Impact of Isoniazid and Rifampicin on Chemokines with Clinical Parameters in Tuberculosis Patients

0Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.
Get full text

Abstract

One of the most common and deadly diseases is tuberculosis, which has been known to be originated in ancient times. The assessment of the effectiveness of treatment regimens involves the monitoring of adverse events and the estimation of biomarkers. Serum biomarkers: Chemokine, Hematology, Liver function tests, and Kidney function tests were studied in forty tuberculosis patients of pulmonary and extra-pulmonary with its correlation. The monitoring and follow-up were assessed for the presence of any adverse effects, and compliance to treatment by Isoniazid 300 mg/kg, and Rifampicin 600 mg/kg during the study period. A significant difference was recorded between pulmonary and extra-pulmonary patients of the serum chemokine CXCL8 after one and two months of the treatment. The serum CXCL8 was increased in pulmonary and decreased in extra-pulmonary TB patients. The conclusion of this study described that chemokines play a role in mediating an effective immune-modulatory role during the treatment of TB infection and the therapeutic drug monitoring for compliance with TB treatment. A significant difference was noticed in the levels of liver enzymes (AST and ALT) between pulmonary and extra-pulmonary tuberculosis. Kidney function parameters showed a difference in creatinine levels between the two studied groups.

Cite

CITATION STYLE

APA

Altaei, A. O. T. (2023). Impact of Isoniazid and Rifampicin on Chemokines with Clinical Parameters in Tuberculosis Patients. Biomedical and Pharmacology Journal, 16(1), 611–627. https://doi.org/10.13005/bpj/2644

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free